D Cibrik
Overview
Explore the profile of D Cibrik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
381
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakhuja A, Naik A, Amer H, Cibrik D, Eikstadt R, Schold J, et al.
Am J Transplant
. 2016 Feb;
16(3):1007-14.
PMID: 26845755
Preemptive kidney transplant (PKTx) and kidney transplant (KTx) within 1 year of dialysis initiation have been associated with superior outcomes. Wait times should be minimal for transplants with living donors;...
2.
Vincenti F, Tedesco Silva H, Busque S, OConnell P, Friedewald J, Cibrik D, et al.
Am J Transplant
. 2012 Jun;
12(9):2446-56.
PMID: 22682022
In this Phase 2b study, 331 low-to-moderate risk de novo kidney transplant patients (approximately 60% deceased donors) were randomized to a more intensive (MI) or less intensive (LI) regimen of...
3.
Cibrik D, Arcona S, Vasquez E, Baillie G, Irish W
Transplant Proc
. 2011 Sep;
43(7):2562-7.
PMID: 21911123
Background: Limited long-term data exist on US kidney transplant patients who have received everolimus at time of transplantation. Methods: Using data from the United Network for Organ Sharing/Organ Procurement Transplant...
4.
Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, et al.
Am J Transplant
. 2011 May;
11(7):1444-55.
PMID: 21564523
Sotrastaurin, a selective protein-kinase-C inhibitor, blocks early T-cell activation through a calcineurin-independent mechanism. In this study, de novo renal transplant recipients with immediate graft function were randomized 1:2 to tacrolimus...
5.
Tedesco Silva Jr H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, et al.
Am J Transplant
. 2010 May;
10(6):1401-13.
PMID: 20455882
Everolimus allows calcineurin-inhibitor reduction without loss of efficacy and may improve renal-transplant outcomes. In a 24-month, open-label study, 833 de novo renal-transplant recipients were randomized to everolimus 1.5 or 3.0...
6.
Gaston R, Kaplan B, Shah T, Cibrik D, Shaw L, Angelis M, et al.
Am J Transplant
. 2009 May;
9(7):1607-19.
PMID: 19459794
Mycophenolate mofetil (MMF) was developed with cyclosporine as a fixed-dose immunosuppressant. More recent data indicate a relationship between mycophenolic acid (MPA) exposure in individuals and clinical endpoints of rejection and...
7.
Luan F, Zhang H, Schaubel D, Miles C, Cibrik D, Norman S, et al.
Am J Transplant
. 2008 Sep;
8(9):1871-7.
PMID: 18786231
New onset diabetes after transplantation (NODAT) and impaired fasting glucose (IFG) are common in kidney transplant recipients (KTRs). Calcinuerin inhibitor (CNI) therapy is a causal risk factor. NODAT is associated...
8.
Luan F, Chopra P, Park J, Norman S, Cibrik D, Ojo A
Transplant Proc
. 2006 Dec;
38(10):3673-5.
PMID: 17175363
Cytomegalovirus (CMV) disease is relatively common following solid organ transplant, particularly if a serologically negative recipient receives an organ from a serologically positive donor (D+/R-). Although valganciclovir is approved for...
9.
Ojo A, Meier-Kriesche H, Hanson J, Leichtman A, Magee J, Cibrik D, et al.
Transplantation
. 2001 Feb;
71(1):82-90.
PMID: 11211201
Background: Simultaneous pancreas-kidney transplantation (SPK) ameliorates the progression of microvascular diabetic complications but the procedure is associated with excess initial morbidity and an uncertain effect on patient survival when compared...
10.
Meier-Kriesche H, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa L, et al.
Transplantation
. 2001 Feb;
69(5):885-9.
PMID: 10755545
No abstract available.